Research Triangle Park, North Carolina-based Asensus made the sale to its distribution partner. The latest sale of Senhance means the system will be placed in a hospital in the Commonwealth of Independent States region, which includes Russia and many other former Soviet republics. It marks the second system sold in the region in the past month.
“We are excited to be partnering with yet another institution to initiate a Senhance program to deliver better patient outcomes,” noted Anthony Fernando, President and CEO of Asensus Surgical. “Hospitals continue to recognize the value of our advanced digital laparoscopic platform, which leverages Augmented Intelligence to enable consistently superior outcomes. We’re particularly enthusiastic about hospitals continuing to adopt Senhance, highlighting the system’s clinical relevance and value.”
Asensus designed Senhance for use in general laparoscopic and laparoscopic gynecological procedures. The company won FDA clearance for the system in 2017. Since then, it secured expanded indications, deals with Google and Nvidia, and hospital placements around the world.
Senhance became the first and only digital laparoscopic surgery system for children when the FDA cleared its pediatric indication in March.
In recent months, the company has reported plenty of positives for the Senhance platform. Last month, Asensus announced a Senhance placement in Germany. That came after Mayo Clinic recently took up a pediatric program in the U.S., while the company also has several programs ongoing in Japan.
However, one negative came last month when the company had an FDA Class I recall for the system due to malfunctions causing unintended movement.